Insider Selling: Alexion Pharmaceuticals EVP Unloads 3,574 Shares of Stock (ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) EVP Martin Mackay sold 3,574 shares of Alexion Pharmaceuticals stock on the open market in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $160.85, for a total transaction of $574,877.90. Following the completion of the transaction, the executive vice president now directly owns 24,426 shares of the company’s stock, valued at approximately $3,928,922. The sale was disclosed in a filing with the SEC, which is available at this link.
Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.26% on Thursday, hitting $157.71. The stock had a trading volume of 1,175,078 shares. Alexion Pharmaceuticals has a 52 week low of $87.01 and a 52 week high of $185.43. The stock’s 50-day moving average is $152.3 and its 200-day moving average is $145.9. The company has a market cap of $31.194 billion and a P/E ratio of 96.57.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, April 24th. The company reported $1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.27. The company had revenue of $566.60 million for the quarter, compared to the consensus estimate of $560.22 million. During the same quarter in the previous year, the company posted $0.65 earnings per share. The company’s revenue for the quarter was up 67.2% on a year-over-year basis. On average, analysts predict that Alexion Pharmaceuticals will post $4.86 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, May 9th. They now have a $210.00 price target on the stock, up previously from $200.00. Separately, analysts at Zacks reiterated an “outperform” rating on shares of Alexion Pharmaceuticals in a research note on Friday, April 25th. They now have a $187.00 price target on the stock. Finally, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, April 25th. They now have a $220.00 price target on the stock, up previously from $219.00. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $182.31.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.